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MaIt is now known that cells do not always die by apoptosis, but can also undergo a process known as programmed cell
necrosis, or necroptosis. In a study recently published in Science Advances, investigators reported that this proinﬂam-
matory process is active in human atherosclerosis, may promote growth of the necrotic core, and may serve as a novel
molecular imaging and translational therapeutic target. These ﬁndings represent a major step in our goal to reduce
coronary disease and stroke. (J Am Coll Cardiol Basic Trans Science 2016;1:548–50) © 2016 The Author. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I t has been estimated that the human body turnsover billions of cells per day. Most of these cellsdie via a noninﬂammatory process known as pro-
grammed cell death, or apoptosis. Under physiological
conditions, these cells are recognized and cleared via
a highly efﬁcient process known as programmed cell
removal, or efferocytosis. This process occurs in
what has been described as an immunologically-
silent manner, with the vast majority of apoptotic cells
being phagocytosed before they have a chance to un-
dergo secondary necrosis. For these reasons, investi-
gators have long wondered why necrotic debris
accumulates during atherogenesis, and studies have
investigated whether efferocytosis may be defective
as plaques develop (1–3).
It is now known, however, that apoptosis is not the
only way in which a cell can commit suicide. A pro-
cess known as programmed cell necrosis, or “nec-
roptosis,” has recently been described (4). Unlike
apoptosis, necroptosis appears to result in an in-
ﬂammatory form of cell death, which may have
evolved as a host defense against viral infection or
other forms of cellular injury. This process occurs
when proapoptotic caspase enzymes are exhausted orm the Divisions of Vascular Surgery and Cardiovascular Medicine, Stanfor
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membranes, which causes the release of previously
sequestered proinﬂammatory intracellular contents.
Emerging studies have suggested that necroptosis
may play a role in a number of inﬂammatory condi-
tions and human diseases. In a study recently pub-
lished by Karunakaran et al. (5) in Science Advances,
the authors asked whether this process may also be
active in human atherosclerotic disease, and if it
might serve as a novel translational target (Figure 1).
The authors began by showing that the critical
pronecroptotic factors RIP3 and MLKL are present and
activated in human atherosclerotic plaque. Moreover,
they found that the factors are preferentially up-
regulated in subjects with unstable compared with
stable disease (e.g., in carotid surgery patients who
presented with stroke or TIA as opposed to those with
incidentally-detected stenoses). Together, these data
provide the ﬁrst evidence that necroptotic pathways
are associated with human vascular disease and may
correlate with lesion vulnerability.
Next, the authors explain the mechanism by which
necroptosis is activated in cardiovascular disease by
showing that oxidized low-density lipoproteind University School of Medicine, Stanford, California.
1 and R01HL12337001). Dr. Leeper is a co-founder of
FIGURE 1 Necroptosis in Cardiovascular Disease
LDL ¼ low-density lipoprotein; TNF ¼ tumor necrosis factor.
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549directly stimulates pronecroptotic signaling cascades,
including phosphorylation of the canonical factor
RIP3. This pathway is shown to involve reactive
oxygen species and damage-associated molecular
patterns, which in turn render these cells resistant to
efferocytic clearance. These ﬁndings are important
as they link causal pro-atherosclerotic factors that are
known to be up-regulated in the diseased vesselwall (such as dyslipidemia and oxidative stress) to
signaling that promotes necroptosis, beyond their ef-
fects on apoptosis.
In vivo, a novel radiotracer developed with a factor
that targets the necroptotic pathway was shown to
speciﬁcally localize to the atherosclerotic plaque in
mouse models of vascular disease. Finally, the au-
thors conﬁrmed that an orally-available necroptosis
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550inhibitor known as necrostatin-1 promoted features
of plaque stability in atheroprone Apoe/ mice who
were fed a high-fat diet, and even reduced plaque size
in animals with established lesions. These ﬁndings
are of interest because the therapy appears to be
nontoxic and is able to reduce the size of the necrotic
core without having an effect on plasma lipid levels.
TRANSLATIONAL RELEVANCE
Although great strides have been made with risk
factor-reducing approaches such as lipid lowering,
antiplatelet, and antihypertensive therapies, there is
a need to understand the root cause and pathobiology
of atherosclerosis to develop novel translational
therapies for myocardial infarction and stroke. The
ﬁnding that necroptosis is active in the vessel wall of
humans and may promote the growth of the necrotic
core represents an important step forward. Of inter-
est, there is currently an ongoing study examining the
molecular triggers of necroptosis in human neutro-
phils of healthy volunteers (NCT02385331).Many studies have shown methods to either di-
agnose or prevent atherosclerosis in mice. Very few
can do both at the same time, and even fewer have
shown efﬁcacy in established lesions, which is
essential in the clinical setting. Perhaps even more
importantly, the pathway identiﬁed in the current
study represents a readily “druggable” target, as
opposed to a candidate gene that may prove difﬁcult
to modulate in vivo without off-target effects. The
exciting study by Karunakaran et al. (5) may allow for
the development of an orally-available “theranostic”
for imaging and treating vulnerable plaques that
contain necrotic tissue cores, which would represent
a signiﬁcant breakthrough in the treatment of
atherosclerotic cardiovascular disease.
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